Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Replagal

- PMLiVE

UK government and GSK/Sanofi sign COVID-19 vaccine supply deal

UK adds to its arsenal of potential vaccine candidates

- PMLiVE

NICE recommends Astellas’ Xospata for NHS use

Cost-effectiveness watchdog backtracks on previous rejection

- PMLiVE

Britain closes in on £500m COVID-19 vaccine deal with Sanofi/GSK

Alleged deal could include agreement for 60 million doses

Sanofi reception

Sanofi doses first patient in global Kevzara COVID-19 trial

Sanofi is leading trials outside the US while Regeneron is leading US trials

- PMLiVE

In virtual meeting, CHMP backs Sanofi’s myeloma drug Sarclisa

Monthly meeting held remotely for the first time due to COVID-19 pandemic

- PMLiVE

NICE looks internally for new chief executive

Deputy chief exec Gillian Leng is set to take the helm

- PMLiVE

Sanofi, Regeneron launch trials of arthritis drug Kevzara for COVID-19

The interleukin-6 inhibitor will be evaluated in critically ill patients

- PMLiVE

Mergers and acquisitions: agents for change

Getting the best from your agency in a disruptive time

Bedrock Healthcare Communications

Sanofi reception

FDA approves Sanofi’s key cancer drug Sarclisa for myeloma

First cancer drug wholly owned by company to be approved in past decade

- PMLiVE

Celgene’s Revlimid scores NICE approval in follicular lymphoma

New ‘chemotherapy-free’ treatment for patients with limited options

Sanofi reception

Sanofi says it will spin out active ingredient business by 2022

New chief exec Paul Hudson continues revamp

- PMLiVE

As new coronavirus outbreaks emerge, fears of a global pandemic escalate

Increased quarantine measures are reported across the globe

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links